News > Network meta-analysis compares DOACs to LMWH for cancer linked thrombosis

Network meta-analysis compares DOACs to LMWH for cancer linked thrombosis

Direct oral anticoagulants (DOACs) are more effective and cost-effective than low-molecular-weight heparin for cancer-associated thrombosis (CAT), with the results sensitive to monthly drug costs, according to research published online in the Annals of Internal Medicine. Compared with apixaban, rivaroxaban was slightly more effective, with an incremental cost-effectiveness ratio (ICER) of $493,246.